^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Malignant Pleural Mesothelioma

    Related cancers:
    Apply
    Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma (NCT04040231)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    07/24/2019
    Primary completion :
    07/01/2024
    Completion :
    07/01/2024
    WT1
    |
    Opdivo (nivolumab) • Zeltherva (galinpepimut-S) • Leukine (sargramostim)
    Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (NCT04491942)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    08/25/2021
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    cisplatin • gemcitabine • elimusertib (BAY 1895344) • liposomal gemcitabine (FF-10832)
    A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers (NCT05337735)
    Phase 2
    M.D. Anderson Cancer Center
    Suspended
    Last update posted :
    06/04/2024
    Initiation :
    08/05/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    MSI
    |
    MSI-H/dMMR
    |
    vudalimab (XmAb717)
    Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease (NCT04836429)
    Phase 1
    Roswell Park Cancer Institute
    Suspended
    Last update posted :
    06/04/2024
    Initiation :
    03/10/2022
    Primary completion :
    03/17/2025
    Completion :
    03/17/2025
    PD-L1
    |
    PD-L1 expression
    |
    Photofrin (porfimer sodium)
    Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma (A082101) (NCT05647265)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    03/14/2023
    Primary completion :
    12/15/2024
    Completion :
    12/15/2024
    PD-L1 • ALK
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (NCT02414269)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    05/01/2015
    Primary completion :
    04/30/2025
    Completion :
    04/30/2025
    PD-L1 • MSLN
    |
    MSLN expression
    |
    Keytruda (pembrolizumab) • cyclophosphamide • cyclophosphamide intravenous • iCasp9M28z T cell infusion
    Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma (Immuno-MESODEC) (NCT05765084)
    Phase 1/2
    University Hospital, Antwerp
    Recruiting
    Last update posted :
    05/16/2024
    Initiation :
    02/24/2023
    Primary completion :
    10/01/2026
    Completion :
    10/01/2026
    WT1
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed
    Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors (NCT03074513)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/16/2024
    Initiation :
    03/03/2017
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    CD4
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Pembrolizumab in Treating Patients With Malignant Mesothelioma (NCT02399371)
    Phase 2
    University of Chicago
    Active, not recruiting
    Last update posted :
    05/13/2024
    Initiation :
    03/31/2015
    Primary completion :
    03/20/2026
    Completion :
    03/20/2026
    PD-L1 • CD8
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma (NCT04577326)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    05/01/2024
    Initiation :
    09/30/2020
    Primary completion :
    09/30/2024
    Completion :
    09/30/2024
    MSLN
    |
    MSLN expression
    |
    cyclophosphamide • ATA2271 • cyclophosphamide intravenous • engineered autologous T cells
    Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors (NCT05228015)
    Phase 1
    Ikena Oncology
    Recruiting
    Last update posted :
    04/12/2024
    Initiation :
    01/07/2022
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    YAP1 • TFE3 • CAMTA1 • TAFAZZIN
    |
    TFE3 fusion
    |
    Tagrisso (osimertinib) • IK-930
    A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (NCT05451849)
    Phase 1/2
    TCR2 Therapeutics
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    06/21/2022
    Primary completion :
    10/30/2028
    Completion :
    10/30/2028
    MSLN
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • TC-510
    Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852)
    Phase 1/2
    TCR2 Therapeutics
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    04/15/2019
    Primary completion :
    11/02/2028
    Completion :
    11/02/2028
    MSLN
    |
    MSLN expression • MSLN positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV
    Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU) (NCT04300244)
    Phase 2
    Åslaug Helland
    Active, not recruiting
    Last update posted :
    02/29/2024
    Initiation :
    05/04/2020
    Primary completion :
    03/15/2025
    Completion :
    03/15/2027
    TMB
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Leukine (sargramostim) • UV1
    Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin (NCT05375825)
    Phase 1
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/01/2024
    Initiation :
    02/06/2024
    Primary completion :
    12/18/2024
    Completion :
    12/18/2024
    MSLN
    |
    MSLN expression • MSLN positive
    |
    LMB-100
    CAR T Cells in Mesothelin Expressing Cancers (NCT03054298)
    Phase 1
    University of Pennsylvania
    Active, not recruiting
    Last update posted :
    01/24/2024
    Initiation :
    04/06/2017
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    PD-L1
    |
    MSLN expression
    |
    cyclophosphamide • fludarabine IV • TmMSTN-01
    SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II (NCT04480372)
    Phase 2
    Swiss Group for Clinical Cancer Research
    Active, not recruiting
    Last update posted :
    01/17/2024
    Initiation :
    03/17/2021
    Primary completion :
    05/01/2024
    Completion :
    05/01/2024
    CD4
    |
    Tecentriq (atezolizumab) • gemcitabine
    Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma (NCT03126630)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    01/10/2024
    Initiation :
    10/04/2018
    Primary completion :
    07/08/2023
    Completion :
    09/21/2024
    PD-L1 • MSLN
    |
    PD-L1 expression • MSLN expression
    |
    Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343) • Pembroria (pembrolizumab biosimilar)
    DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R) (NCT04334759)
    Phase 3
    PrECOG, LLC.
    Active, not recruiting
    Last update posted :
    12/01/2023
    Initiation :
    02/18/2021
    Primary completion :
    04/01/2025
    Completion :
    12/01/2025
    PD-L1
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • pemetrexed
    APG-2449 in Patients With Advanced Solid Tumors (NCT03917043)
    Phase 1
    Ascentage Pharma Group Inc.
    Recruiting
    Last update posted :
    11/21/2023
    Initiation :
    05/27/2019
    Primary completion :
    01/01/2025
    Completion :
    02/01/2025
    ALK • ROS1
    |
    ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion
    |
    APG-2449
    Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma (BIMES) (NCT05005429)
    Phase 2
    Fundación GECP
    Recruiting
    Last update posted :
    09/07/2023
    Initiation :
    09/20/2021
    Primary completion :
    03/30/2025
    Completion :
    04/30/2025
    CD4
    |
    bintrafusp alfa (M7824)
    NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours (NCT05714553)
    Phase 1/2
    NuCana plc
    Recruiting
    Last update posted :
    06/23/2023
    Initiation :
    03/08/2023
    Primary completion :
    08/01/2024
    Completion :
    01/01/2025
    MSI
    |
    Keytruda (pembrolizumab) • docetaxel • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium
    Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers (REFIT-MSS) (NCT05582031)
    Phase 2
    Translational Research in Oncology
    Withdrawn
    Last update posted :
    06/07/2023
    Initiation :
    04/30/2023
    Primary completion :
    04/30/2025
    Completion :
    04/30/2025
    MSI
    |
    MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr) • Stivarga (regorafenib)
    A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) (NCT03475953)
    Phase 1/2
    Institut Bergonié
    Recruiting
    Last update posted :
    03/03/2023
    Initiation :
    05/04/2018
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    PD-L1 • BRAF • ALK • TMB • MSI • ROS1 • CTLA4
    |
    TMB-H • ALK positive • ALK mutation • ROS1 positive
    |
    Bavencio (avelumab) • Stivarga (regorafenib)
    Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (PEMMELA) (NCT04287829)
    Phase 2
    The Netherlands Cancer Institute
    Recruiting
    Last update posted :
    01/16/2023
    Initiation :
    03/01/2021
    Primary completion :
    12/05/2024
    Completion :
    12/05/2024
    CTLA4
    |
    Keytruda (pembrolizumab) • cisplatin • Lenvima (lenvatinib)
    MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma (NCT02592551)
    Phase 2
    Baylor College of Medicine
    Completed
    Last update posted :
    09/29/2022
    Initiation :
    05/11/2016
    Primary completion :
    08/06/2019
    Completion :
    09/01/2022
    PD-L1 • CD8 • CD4 • ICOS
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab)
    Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients (NCT01865045)
    Phase N/A
    Armando Santoro, MD
    Completed
    Last update posted :
    09/10/2022
    Initiation :
    11/01/2012
    Primary completion :
    12/01/2016
    Completion :
    12/01/2017
    BRCA1 • TUBB3
    |
    BRCA1 expression • TUBB3 expression
    |
    vinorelbine tartrate
    PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma (PROMISE-meso) (NCT02991482)
    Phase 3
    ETOP IBCSG Partners Foundation
    Completed
    Last update posted :
    08/24/2022
    Initiation :
    09/12/2017
    Primary completion :
    02/20/2019
    Completion :
    11/30/2021
    PD-L1
    |
    Keytruda (pembrolizumab) • gemcitabine • vinorelbine tartrate
    Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung (NCT05228795)
    Phase N/A
    Sohag University
    Recruiting
    Last update posted :
    02/08/2022
    Initiation :
    02/01/2022
    Primary completion :
    06/01/2022
    Completion :
    12/01/2022
    GPC1
    |
    GPC1 expression
    Vinorelbine in Mesothelioma (NCT02139904)
    Phase 2
    Wales Cancer Trials Unit
    Completed
    Last update posted :
    10/12/2021
    Initiation :
    03/01/2016
    Primary completion :
    03/17/2021
    Completion :
    03/17/2021
    BRCA1
    |
    vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma (NCT01644994)
    Phase 2
    University of Zurich
    Completed
    Last update posted :
    09/29/2021
    Initiation :
    11/01/2012
    Primary completion :
    12/01/2019
    Completion :
    08/01/2021
    CDKN1A
    |
    cisplatin
    Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (MAPS2) (NCT02716272)
    Phase 2
    Intergroupe Francophone de Cancerologie Thoracique
    Completed
    Last update posted :
    02/10/2021
    Initiation :
    03/24/2016
    Primary completion :
    02/01/2018
    Completion :
    06/22/2019
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin (NCT02049060)
    Phase 1/2
    Armando Santoro, MD
    Completed
    Last update posted :
    01/22/2021
    Initiation :
    01/01/2013
    Primary completion :
    05/01/2016
    Completion :
    12/01/2017
    MET • HGF
    |
    MET expression
    |
    carboplatin • pemetrexed • tivantinib (ARQ 197)
    Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma (NCT02303899)
    Phase 2
    Istituto Clinico Humanitas
    Completed
    Last update posted :
    01/22/2021
    Initiation :
    11/01/2014
    Primary completion :
    12/01/2015
    Completion :
    12/01/2017
    KIT • PDGFRB
    |
    gemcitabine • imatinib • pemetrexed
    Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma (NCT01503177)
    Phase 1
    Mayo Clinic
    Completed
    Last update posted :
    01/11/2021
    Initiation :
    11/01/2011
    Primary completion :
    04/11/2019
    Completion :
    04/11/2019
    CD4
    |
    MV-NIS
    Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) (NCT02610140)
    Phase 2
    Bayer
    Completed
    Last update posted :
    11/04/2020
    Initiation :
    12/03/2015
    Primary completion :
    05/31/2017
    Completion :
    09/06/2019
    MSLN
    |
    MSLN expression
    |
    pemetrexed • vinorelbine tartrate • anetumab ravtansine (BAY 94-9343)
    Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma (NCT01675765)
    Phase 1b
    Aduro Biotech, Inc.
    Completed
    Last update posted :
    09/30/2020
    Initiation :
    09/03/2014
    Primary completion :
    09/05/2018
    Completion :
    08/19/2019
    MSLN
    |
    cisplatin • cyclophosphamide • pemetrexed • CRS-207 • cyclophosphamide intravenous